The pharmaceutical industry in Bangladesh has transitioned from an import-dependent sector to a sophisticated, technologically advanced manufacturing hub that satisfies approximately 98% of the domestic medicinal demand.1 This evolution, catalyzed by the landmark National Drug Policy of 1982, has positioned the country as a significant player in the global generic market, with exports reaching over 150 countries, including highly regulated markets such as the United States, the United Kingdom, and the European Union.2 As of 2024, the industry is valued at approximately BDT 36,614 crore (USD 3.5 billion) and is projected to surpass USD 6 billion by 2025, maintaining a consistent annual growth rate of 12% to 15%.1 The sector contributes 1.83% to the national GDP and stands as the second-largest taxpayer in the country, reflecting its role as a vital economic engine.1
The strategic importance of this industry is currently being redefined by a shift toward high-value pharmaceutical segments, including oncology, biopharmaceuticals, vaccines, and specialized Active Pharmaceutical Ingredients (APIs).7 This transition is driven by the impending graduation of Bangladesh from its Least Developed Country (LDC) status in November 2026, which will eventually end the flexibilities granted under the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).10 Consequently, the industry is aggressively investing in advanced manufacturing technologies, global regulatory compliance, and backward integration to maintain its competitive edge in the post-graduation era.3
Macro-Economic Landscape and Market Dynamics
The pharmaceutical market in Bangladesh is characterized by a high degree of self-sufficiency and the dominance of local manufacturing firms, which contribute more than 90% of the available medicines.5 The domestic market has witnessed exceptional growth, with valuation projected to grow by 114% between 2019 and 2025.5 This expansion is supported by rising per capita income, an aging population, and a shift in the disease profile from communicable to non-communicable diseases (NCDs) such as cardiovascular disorders, diabetes, and cancer.5
Market Valuation and Growth Forecasts
The pharmaceutical industry has sustained a five-year Compound Annual Growth Rate (CAGR) of 15.6% up to 2022, reaching a market size of USD 3.5 billion.6 Projections indicate that the market will continue to expand at a CAGR of 12% through 2025.5 This growth is further illustrated by the surge in individual healthcare expenditure, which tripled over the last decade from USD 15.8 to USD 41.9 per person.6
The industry’s financial stability is also reflected in its relationship with the banking sector. As of 2023, the pharmaceutical industry accounts for BDT 197.13 billion in outstanding loans, representing only 1.32% of the total outstanding portfolio of the banking sector.1 Notably, the sector maintains the lowest non-performing loan (NPL) ratio at 2.87% among all reported industries, signifying a low-risk, high-growth environment with superior repayment behavior.1
Competitive Structure and Market Share
The market is dominated by large-scale local enterprises, with the top 20 companies holding a combined market share of 92.2% in FY24, an increase from 88.7% in FY19.1 This concentration of market power allows these firms to undertake the heavy capital expenditures required for high-value segments like oncology and biosimilars.1
Square Pharmaceuticals maintains the top position with a significant focus on research and development and sustainable manufacturing practices.4 Beximco Pharmaceuticals, meanwhile, has emerged as a global ambassador for the industry, being the first Bangladeshi firm to receive USFDA approval and maintaining a dominant share of the medicines exported from Bangladesh to the United States.2
Strategic High-Value Segments: Oncology and Biopharmaceuticals
As the industry moves beyond basic generic manufacturing, high-value segments have become the primary focus for investment and expansion. These segments require specialized facilities, advanced technological know-how, and rigorous quality control protocols that align with international standards.2
Oncology Hub and Specialized Facilities
Bangladesh has transitioned from a producer of simple generic pills to a serious player in the global oncology market. Beacon Pharmaceuticals is currently the leading oncology company in the country, with over 70 oncology medicines exported to more than 100 countries.7 These high-potency and sensitive drugs require state-of-the-art facilities designed with ISO-classified cleanrooms and advanced quality control laboratories.7
The oncology manufacturing units must maintain strict control over air handling, pressure differentials, and contamination risks to ensure the safety of both the product and the operators.7 Leading firms like Beacon and Delta Pharma are investing in targeted therapies, immunotherapies, and complex injectable oncology drugs.7 Delta Pharma recently announced a long-term USD 100 million investment in the Noakhali Special Economic Zone (NSEZ) specifically for biopharma and oncology production, employing AI-driven production techniques to enhance efficiency.17
Biopharmaceuticals and Biosimilars Development
Biopharmaceuticals, particularly biosimilars, represent a critical frontier for the industry. Biosimilars are highly similar versions of innovator biologic products and offer effective treatments for chronic conditions such as diabetes, rheumatoid arthritis, and cancer at a 10% to 30% lower cost.16
A landmark achievement in this sector is the local production of Adalimumab, used for rheumatic diseases. Through the LDC TRIPS waiver, local companies were able to master end-to-end manufacturing capacity—from cell lines to fill-finish—reducing the cost per dose to approximately BDT 15,000.19 Incepta, Beacon, and Renata are among the companies that have invested in mastering cell culture, fermentation, and downstream purification to produce these complex large-molecule drugs.16
Vaccine Manufacturing and Public Health Resilience
The establishment of domestic vaccine manufacturing facilities is a top priority for national health security. The government, supported by a USD 300 million loan from the Asian Development Bank (ADB), is establishing a massive facility in Gopalganj to manufacture 13 types of vaccines, including those for COVID-19.21 Private sector players like Incepta have already established significant vaccine production lines, contributing to the country’s pandemic response and overall public health infrastructure.4
Regulatory Framework and Global Compliance Standards
The Directorate General of Drug Administration (DGDA) serves as the primary regulatory body, overseeing the licensing, registration, and quality control of all pharmaceutical products in Bangladesh.23 The regulatory landscape is governed by the Drug Act of 1940 and the Drug Policy of 2016, which emphasize alignment with World Health Organization (WHO) standards.24
Manufacturing Licensing and Registration Procedures
To establish a pharmaceutical factory, companies must navigate a multi-step regulatory pathway, including company formation, land purchase, environmental clearance, and project profile submission to the DGDA.23
The registration of finished medicines is valid for five years, while API source validation is required every three years.23 For new drug registrations, companies must submit a comprehensive product dossier, often following the International Conference on Harmonisation (ICH) Common Technical Document (CTD) format, which includes stability data, manufacturing processes, and preclinical/clinical trial results.24
GMP Compliance and International Certification
Good Manufacturing Practice (GMP) is the cornerstone of pharmaceutical quality. The DGDA sets these regulations, and obtaining GMP certification is essential for legal operation and export success.26 Leading Bangladeshi firms prioritize compliance with stringent international standards, including USFDA, UK MHRA, EU GMP, and TGA Australia, to access highly regulated markets.2
The DGDA is currently working toward achieving Maturity Level 3 (ML3) under the WHO Global Benchmarking Tool to enhance its regulatory credibility and facilitate easier WHO Prequalification for local products.9 Furthermore, Bangladesh has applied for pre-accession to the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which would harmonize its GMP inspection standards with 57 other global jurisdictions.27
Backward Integration: The API Industry and Raw Materials
A significant strategic challenge for the Bangladeshi pharmaceutical sector is its heavy reliance on imported raw materials. Approximately 90% to 95% of Active Pharmaceutical Ingredients (APIs) used in domestic production are imported, primarily from China (40%) and India (30%).1 This dependency exposes the industry to supply chain disruptions and price volatility, with APIs accounting for 30% to 55% of total drug costs for generics.8
The API Industrial Park (Munshiganj)
To build a self-reliant ecosystem, the government established a 200-acre API Industrial Park in Munshiganj.2 This park, managed by the Bangladesh Small and Cottage Industries Corporation (BSCIC), contains 42 plots allocated to 27 leading companies, including Square, Beximco, and Incepta.13 The park is designed to host a Common Effluent Treatment Plant (CETP) and a waste dumping yard to manage the environmental impact of chemical synthesis.13
As of early 2025, the park's development has faced infrastructure hurdles. While Healthcare Chemicals and Axis Pharmaceuticals have established plants, many other plots remain unused due to inconsistent power and gas supplies.31 Accelerating the operationalization of this park is considered vital, as it is expected to save up to 70% of the import cost of raw materials.13
API Policy 2018 and Financial Incentives
The National API Policy 2018 aims to reduce raw material import reliance from 97% to 80% by 2032 and attract USD 1 billion in investment.8 To incentivize local API synthesis, the government offers a range of benefits:
Currently, only about 15 local companies produce around 40 different API molecules, with Gonoshasthaya Pharmaceuticals Limited (GPL) accounting for 60% of locally manufactured APIs.8 The successful implementation of the API policy is critical for sustaining the industry beyond the TRIPS waiver period.13
Infrastructure and Technical Design Requirements
High-value pharmaceutical manufacturing requires stringent environmental controls and sophisticated engineering solutions to ensure product safety and regulatory compliance. The design of a pharmaceutical plant must integrate cleanroom classifications, HVAC systems, and water purification standards that meet international expectations.33
HVAC Systems and Cleanroom Classification
The Heating, Ventilation, and Air Conditioning (HVAC) system is perhaps the most critical utility in a pharmaceutical plant. It must control temperature (typically 18°C to 25°C), relative humidity (40% to 60%), and air purity through HEPA filtration.33
To prevent cross-contamination, plants utilize "pressure cascades," where cleaner areas are kept at a higher positive pressure (+15 Pa) relative to less-clean zones, ensuring air flows out of critical areas.33 In facilities handling potent oncology drugs or biological agents, negative pressure systems are used to contain hazardous materials and protect the external environment.33
Water for Injection (WFI) and Purified Water Systems
For sterile injectables and liquid formulations, high-purity water is essential. Purified Water (PW) and Water for Injection (WFI) systems must be designed to prevent microbial growth and biofilm formation. This involves continuous circulation, temperature control, and the use of stainless steel (316L) piping with orbital welding to ensure smooth, cleanable surfaces.36
Advanced Machinery and Equipment
Leading high-value plants in Bangladesh utilize machinery from premium global manufacturers to ensure compliance with USFDA and EMA requirements.
While basic equipment such as mixers or simple tablet presses can be sourced locally at lower costs (e.g., BDT 180,000 for a single punch machine), a high-value facility requires the reliability and validation documentation provided by international brands.37
Project Economics and Feasibility Analysis
The setup and operation of a high-value pharmaceutical manufacturing plant involve significant capital expenditure (CAPEX) and recurring operating expenses (OPEX). Financial viability depends on achieving economies of scale and accessing export markets.41
Capital Expenditure (CAPEX) Breakdown
The initial investment for a standard pharmaceutical manufacturing unit in Bangladesh ranges from BDT 20 crore to over BDT 150 crore, depending on the scale and product focus.1 High-value segments like oncology or vaccines require even higher investments, often exceeding USD 50 million to USD 100 million.17
For an oncology facility, specialized sterile infrastructure can drive the cost of cGMP space to USD 600 per square foot, with total facility costs reaching USD 50 million to USD 500 million depending on the antigens produced.43
Operating Expenditure (OPEX) and Profitability
Operating costs are driven by raw material consumption, manpower, and utilities. APIs and raw materials typically account for 40% to 50% of total OPEX.41
Profitability in the sector is generally high. A modeled pharmaceutical plant achieving USD 150 million in revenue can project gross profit margins of 17% to 18% and net profit margins of 13% to 14%.42 The payback period for a well-managed medium-scale unit is typically 2.5 to 3 years, with a Return on Investment (ROI) of approximately 46%.40
Strategic Outlook: LDC Graduation and the Patent Regime
The most pressing challenge for the Bangladeshi pharmaceutical industry is the impending graduation from LDC status on November 24, 2026.11 As an LDC, Bangladesh is exempt from enforcing pharmaceutical patents under the WTO TRIPS agreement until 2033.9
The Impact of TRIPS Waiver Expiry
Losing the TRIPS waiver will force the USD 3.5 billion domestic industry to comply with international patent regimes. This is expected to have several critical impacts:
Generic Production Rights: The ability to produce generic versions of patented medicines without licensing will end.3
Production Costs: Royalty payments to patent holders will increase production expenses, potentially hiking local medicine prices.3
Market Access: Exporting to other LDCs or non-WTO countries may become more complex once Bangladesh is no longer an LDC.8
Import Vulnerability: Patent protection could hinder the local manufacturing of APIs for new drugs, increasing dependency on imports from China or India.3
Strategic Roadmap for 2026 and Beyond
To mitigate the "graduation shock," the Center for Policy Dialogue (CPD) and industry leaders have recommended several strategic actions:
Accelerated Product Launch: Companies are urged to introduce as many patented goods as possible before 2026 to secure their presence in the market.3
Diversification into Complex Generics: Shifting focus to difficult-to-make products like biosimilars, hormones, and anti-cancer drugs where competition is lower and margins are higher.9
R&D and AI Integration: Increasing investment in research and digital tools like AI to accelerate drug development and maintain cost competitiveness.3
Global Regulatory Approvals: Securing USFDA and EMA certifications to enable manufacturing under contract for global firms and participation in off-patent export markets.3
Trade Negotiations: Seeking a 12-year trade grace period or a specific extension of the TRIPS waiver until 2034 through the WTO ministerial meetings.44
Expanding Global Footprint and Export Potential
The pharmaceutical industry has become the second-largest potential earner of foreign currency for Bangladesh.15 Exports reached USD 213 million in FY 2024-2025, a significant increase from previous years.1
Export Destinations and Strategy
Bangladeshi pharmaceuticals are currently exported to 166 nations.1 While Sri Lanka, Myanmar, and Vietnam are large markets, the industry is increasingly penetrating regulated markets like the United States.3 Beximco Pharmaceuticals currently sources 90% of the medications supplied from Bangladesh to the US.6
The export strategy focuses on leveraging the cost advantage—estimated to be 15% lower than India and China—and utilizing the TRIPS waiver until 2033 to supply affordable generics to other developing nations.2
Government Support for Exports
To sustain export growth, the government provides several key supports:
Export Subsidy: 6% cash incentive for finished medicine exports and 5% for APIs.2
Export Trophies: Recognition of top performers to encourage international branding.4
Bilateral Agreements: Efforts to secure free trade agreements (FTAs) to preserve duty-free access post-graduation.11
Infrastructure Allotments in Special Economic Zones
The development of Special Economic Zones (SEZs) by the Bangladesh Economic Zones Authority (BEZA) provides a world-class environment for pharmaceutical investment.
Bangabandhu Sheikh Mujib Shilpa Nagar (BSMSN)
As a 30,000-acre industrial city, BSMSN offers dedicated zones for pharmaceutical production. Healthcare Pharmaceuticals is investing USD 423 million on 40 acres to establish five units for formulations, biotech, and APIs.46 The facility is expected to be a cornerstone of the country's biotech expansion.46
Noakhali Special Economic Zone (NSEZ)
Delta Pharma's USD 100 million investment in NSEZ highlights the regional diversification of the industry.17 The focus on AI-driven production for oncology and biopharmaceuticals in this zone indicates the industry's drive toward Industry 4.0 standards.17
Conclusion: The Resilience and Future of Bangladesh Pharma
The high-value pharmaceutical industry in Bangladesh stands as a testament to strategic industrial policy and private-sector ingenuity. From achieving 98% self-sufficiency to establishing a presence in the world's most regulated markets, the sector has demonstrated remarkable resilience.1 However, the impending graduation from LDC status necessitates a rapid transformation from simple imitation to advanced innovation and backward integration.3
The future growth of the sector (projected to exceed USD 6 billion by 2025) will be driven by oncology, biopharmaceuticals, and local API production.5 By leveraging dedicated infrastructure like the API Industrial Park and Bangabandhu Sheikh Mujib Shilpa Nagar, and by pursuing global regulatory milestones like WHO ML3 and PIC/S membership, the industry is well-positioned to remain a global hub for affordable, high-quality medicine.9 The transition from the TRIPS regime to a fully compliant patent environment will undoubtedly be challenging, but the current levels of investment in high-value capabilities suggest that the Bangladeshi pharmaceutical industry is prepared to navigate the post-2026 landscape as a resilient and competitive global player.
Works cited
Pharmaceutical Industry in Bangladesh: Upholding Global Standards, Expanding Global Reach - IDLC Home, accessed February 24, 2026, https://mbr.idlc.com/industry-insight/pharmaceutical-industry-in-bangladesh-upholding-global-standards-expanding-global-reach
Bangladesh Pharmaceutical & API Industry - BIDA, accessed February 24, 2026, https://investbangladesh.gov.bd/investment-sector/pharma-api
Accelerating the Growth of Bangladesh's Pharmaceutical ... - CPD, accessed February 24, 2026, https://cpd.org.bd/resources/2025/01/Accelerating-the-Growth-of-Bangladeshs-Pharmaceutical-Industry.pdf
Best Pharmaceutical Companies in Bangladesh 2026 - Kothay Blog, accessed February 24, 2026, https://resources.kothay.app/best-pharmaceutical-companies-in-bangladesh/
Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025, accessed February 24, 2026, https://www.researchandmarkets.com/reports/5125539/bangladesh-pharmaceutical-market-future
Pharmaceuticals - Invest Bangladesh, accessed February 24, 2026, https://investbangladesh.co/pharmaceuticals/
Innovation in Oncology Drugs for Modern Cancer Treatment - Beacon Pharmaceuticals, accessed February 24, 2026, https://global.beaconpharma.com.bd/innovation-in-oncology-drugs-for-modern-cancer-treatment
Bangladesh Boosts R&D to Reduce API Dependence - Upturn, accessed February 24, 2026, https://www.upturn.com.bd/categories-blogs/api-dependency-in-bd
Bangladesh in Transition: Political Change and Pharmaceutical Growth, accessed February 24, 2026, https://cordobarg.com/bangladesh-in-transition-political-change-and-pharmaceutical-growth/
Bangladesh Pharma Sector Post-LDC Graduation | PDF | Trips Agreement | Pharmaceutical Industry - Scribd, accessed February 24, 2026, https://www.scribd.com/document/893962804/Accelerating-the-Growth-of-Bangladeshs-Pharmaceutical-Industry
Bangladesh's LDC Graduation: 2026 or Delay to 2032? - BBF Digital, accessed February 24, 2026, https://bbf.digital/bangladeshs-ldc-graduation-2026-or-delay-to-2032
Export Policy 2024-2027 Ministry of Commerce - The Bangladesh Trade Portal, accessed February 24, 2026, https://www.bangladeshtradeportal.gov.bd/kcfinder/upload/files/Legal_1756180440.pdf
Active Pharmaceutical Ingredient (API) Manufacturing: The Next ..., accessed February 24, 2026, https://lightcastlepartners.com/insights/2021/08/active-pharmaceutical-ingredient-api-manufacturing-the-next-growth-driver-of-the-bangladesh-pharmaceutical-industry/
(PDF) Export Dynamics of the Pharmaceutical Industry in Bangladesh - ResearchGate, accessed February 24, 2026, https://www.researchgate.net/publication/397730160_Export_Dynamics_of_the_Pharmaceutical_Industry_in_Bangladesh
Pharmaceutical Sector of Bangladesh: Prospects and Challenges - CORE, accessed February 24, 2026, https://files01.core.ac.uk/download/pdf/61804208.pdf
Parenteral Administration of Biosimilar Products: Bangladesh Perspectives - ResearchGate, accessed February 24, 2026, https://www.researchgate.net/publication/396803899_Parenteral_Administration_of_Biosimilar_Products_Bangladesh_Perspectives
Delta Pharma to invest $100m in NSEZ for biopharma, oncology, AI-driven production, accessed February 24, 2026, https://www.tbsnews.net/economy/delta-pharma-invest-100m-nsez-biopharma-oncology-ai-driven-production-1238991
Realizing Biosimilar Potential in the Middle East & Africa - IQVIA, accessed February 24, 2026, https://www.iqvia.com/-/media/iqvia/pdfs/mea/white-paper/biosimilar_iqvia-whitepaper_final.pdf
A new dawn in rheumatic disease care: Bangladesh's leap into biosimilars, accessed February 24, 2026, https://www.tbsnews.net/thoughts/new-dawn-rheumatic-disease-care-bangladeshs-leap-biosimilars-1268041
5 Editorial: Biosimilars are becoming indispensable in the management of multiple diseases although concerns still exist Brian G - Bangladesh Journals Online, accessed February 24, 2026, https://www.banglajol.info/index.php/BJMS/article/view/50338/36228
Bangladesh to set up 1st-ever vaccine manufacturing facility - Anadolu Ajansı, accessed February 24, 2026, https://www.aa.com.tr/en/world/bangladesh-to-set-up-1st-ever-vaccine-manufacturing-facility/2928367
Vaccines, Therapeutics, and Diagnostics Manufacturing and Regulatory Strengthening Project, accessed February 24, 2026, https://www.adb.org/sites/default/files/project-documents/56289/56289-001-rrp-en.pdf
Drug manufacturing license - Pharma DRA, accessed February 24, 2026, https://pharmadra.net/drug-manufacturing-license/
GMP Compliance and Inspection Standards in Bangladesh – pharma gxp, accessed February 24, 2026, https://www.pharmaregulatory.in/gmp-compliance-and-inspection-standards-in-bangladesh-pharma-gxp/
Bangladesh (DGDA – Directorate General of Drug Administration) - PharmaRegulatory.in, accessed February 24, 2026, https://www.pharmaregulatory.in/country-specific-regulatory-affairs/bangladesh-dgda-directorate-general-of-drug-administration/
Good Manufacturing Practices (GMP) Certification for Pharmaceuticals in Bangladesh, accessed February 24, 2026, https://hmsuniversal.com/gmp-certification-for-pharmaceuticals-in-bangladesh/
PIC/S, accessed February 24, 2026, https://picscheme.org/
Bangladesh applies for PIC/S pre-accession, accessed February 24, 2026, https://picscheme.org/en/news/bangladesh-applies-for-pic-s-pre-accession
News - PIC/S, accessed February 24, 2026, https://picscheme.org/en/news
PHARMACEUTICALS SECTOR IN BANGLADESH, accessed February 24, 2026, https://hcidhaka.gov.in/pdf/Report_on_Pharmaceuticals_Sector_in_Bangladesh(1).pdf
Drug-manufacturing raw material industry fails to take off - Prothom Alo, accessed February 24, 2026, https://en.prothomalo.com/bangladesh/l4mu61zp7o
Bangladesh Export Incentive Rates: FY 2024-2025 - Resource Portal, accessed February 24, 2026, https://resource.ogrlegal.com/exemption-incentive/incentives/
HVAC System Design Requirements for Pharma Manufacturing, accessed February 24, 2026, https://jdpharmaconsultants.co.in/hvac-system-design-requirements-for-pharma-manufacturing/
HVAC Systems for Pharmaceuticals Industry - TROX, accessed February 24, 2026, https://cdn.trox.de/8b0c5fb37fa3bd11/8876e42e79ca/TROX-HVAC-Systems-for-Pharmaceutical-Industry---25.pdf
Air Conditioning Solutions for Pharmaceutical, accessed February 24, 2026, https://aircondition.com.bd/air-conditioning-solutions-for-pharmaceutical/
Clean room requirements for pharmaceuticals: Key design, requirements, and innovations, accessed February 24, 2026, https://kleanlabs.com/blog/clean-room-requirements-for-pharmaceuticals-key-design-requirements-and-innovations/
Top 10 Pharmaceutical Equipment Manufacturers in 2025 - SED Pharma, accessed February 24, 2026, https://sedpharma.com/news-events/pharmaceutical-equipment-manufacturers/
Best 11 Pharmaceutical Equipment Manufacturers in 2025, accessed February 24, 2026, https://www.chinacanaan.com/blog/pharmaceutical-equipment-blog/best-11-pharmaceutical-equipment-manufacturers-in-2025/
Food and Pharmaceuticals Machine Archives - Hydraulic machine Bangladesh, Auto Feed Mill Pellet Machine supplier, accessed February 24, 2026, https://crescentintbd.com/product-category/food-and-pharmaceuticals-machine/
Project Profile of Pharmaceuticals Manufacturing Unit in Bangladesh, accessed February 24, 2026, https://ppb.cbecl.com/project-profile-of-pharmaceuticals-manufacturing-unit-in-bangladesh/
Pharmaceutical Manufacturing Plant Cost, Setup, DPR 2026 - IMARC, accessed February 24, 2026, https://www.imarcgroup.com/pharmaceutical-manufacturing-plant-project-report
IV Solutions Manufacturing Cost Analysis | Case Study - IMARC Group, accessed February 24, 2026, https://www.imarcgroup.com/insight/profitability-cost-analysis-of-iv-solutions-manufacturing-plant-a-detailed-cost-model
Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward - PMC, accessed February 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8986212/
Bangladesh to seek 12-year trade grace for post-graduation era | The Financial Express, accessed February 24, 2026, https://thefinancialexpress.com.bd/home/bangladesh-to-seek-12-year-trade-grace-for-post-graduation-era
(PDF) Strengthening Bangladesh's Pharmaceutical Industry: A Policy, Market and Sustainability Perspective - ResearchGate, accessed February 24, 2026, https://www.researchgate.net/publication/392910494_Strengthening_Bangladesh's_Pharmaceutical_Industry_A_Policy_Market_and_Sustainability_Perspective
Healthcare Pharma to invest $423m at Bangabandhu Shilpa Nagar | The Financial Express, accessed February 24, 2026, https://thefinancialexpress.com.bd/home/healthcare-pharma-to-invest-423m-at-bangabandhu-shilpa-nagar-1611984362
Healthcare Pharmaceuticals starts setting up plant at BSMSN - The Asian Age, accessed February 24, 2026, https://dailyasianage.com/news/253743/healthcare-pharmaceuticals-starts-setting-up-plant-at-bsmsn